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Abstract
In animal models, successful anti-cancer monotherapy with CpG oligodeoxynucleotide (ODN) has
been limited to the intratumoral and peritumoral routes of administration. To overcome this
limitation, we developed a delivery system utilizing an endogenous antibody as a carrier for CpG
ODNs. When a 1:1 conjugate of 2,4-dinitrophenyl (DNP) to a CpG ODN was administered to
tumor-bearing mice that were pre-immunized against DNP, intravenous (IV) administration
successfully inhibited tumor growth.1 In the present studies, we reproduced the IV results and
showed that a DNP derivative of a controlled ODN with scrambled nucleotide sequence failed in
the same model. Perhaps more significantly, contralateral subcutaneous (SC) routes of
administration also suppressed tumor growth. However, in a separate experiment, when the anti-
DNP titer level was low, the anti-tumor effect was abolished, supporting the importance of the
avidity involved in the complexation. With the low titer, a significant fraction of injected dose
must have existed as unbound that is subject to rapid clearance. The present study justifies
chemically crosslink immune complexes such that the CpG ODN cannot dissociate in the body
after administration.
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Introduction
Human immune system reacts against bacterial DNA that contains abundant unmethylated
CpG dinucleotide sequences as a “danger signal” and responds with innate as well as
antigen-specific adaptive immunity. These responses can be harnessed to fight against tumor
growth using a small nucleic acid that contains the CpG dinucleotide motif.2 In essence
CpG-containing ODNs mimic a local inflammation. Indeed intratumorally or peritumorally
administered CpG ODNs of about 20 nucleotides suppress tumor growth.3 However, in
Phase II human clinical studies, IV route was ineffective4 while SC administration produced
only marginal effects.5 In many aspects these disappointing observations mirror the failure
of systemic cytokines in treating tumors, reflecting the lack of their paracrine function in the
tumor microenvironment.6,7 Thus, the pharmacokinetic (PK) requirement in CpG ODN
delivery includes a sustained and targeted delivery to solid tumors. At a (sub)cellular level,
its target is not tumor cells but the endosomal Toll-like receptor 9 of dendritic cells in the
vicinity.2
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Naturally occurring endogenous carriers such as hemoglobin in erythrocytes have evolved to
near perfection through evolution. Binding and dissociation of its ligand oxygen to and from
the protein are cooperative, dictated by oxygen pressure. Similarly the release of fatty acids
bound to albumin critically depends on the serum level of the ligand via step dissociation
involving several binding sites, each with different binding affinity. When xenobiotics latch
on these biopolymers, blood-borne particulates, or cells, it is generally viewed as
undesirable since it affects serum PK and biodistribution of the drug often in unexpected
ways. On the other hand, the endogenous carriers can be exploited for drug delivery as
shown with albumin8 and immunoglobulin.9,10 These two major proteins in human
circulation show almost an identical serum t1/2 of approximately 20 days. Such a long t1/2
originates from protective recycling via so-called Brambell Receptor of FcRn primarily on
endothelium.11
One can envision that the PK of a drug molecule will mimic that of an endogenous carrier
itself if the drug binds the latter with a high affinity. This was found to be the case for small
hapten molecules that can not induce immune clearance via crosslinking.1,12,13 Thus in mice
that were pre-immunized with DNP as a model hapten, DNP derivatives of a CpG ODN
showed a serum t1/2 as long as 3 to 8 days. This in turn allowed the complex to accumulate
at tumor tissue resulting in desirable pharmacological outcome.1 Altered PK and
biodistribution due to binding to endogenous carriers can indeed alter the
pharmacodynamics (PD) of a therapeutic agent as has previously been shown.1 In the
following experiments, mice were immunized against DNP such that they produce
endogenously circulating anti-DNP antibodies. Some mice were subsequently treated with a
therapeutic CpG ODN which had been chemically conjugated to DNP. This article shows




All reagents were purchased from commercial sources and were used without further
purification unless noted otherwise. Molecular biology-grade water, phosphate buffered
saline (PBS), Hank's balanced salt solution (HBSS), thimerosal, Tween 20, complete (CFA)
and incomplete (IFA) Freund's adjuvants were all purchased from Sigma-Aldrich (St. Louis,
MO). Hammersten-grade casein was purchased from Research Organics (Cleveland, OH).
Dinitrophenylated keyhole limpet hemocyanin (DNP-KLH) and DNP-albumin were
purchased from Calbiochem (San Diego, CA). Non-heparinized microcapillary tubes and
Nunc MaxiSorp 96-well plates were purchased from Thermo Fisher Scientific (Waltham,
MA). O-Phenylenediamine dihydrochloride (OPD) and an accompanying buffer were from
Pierce (Rockford, IL). Goat anti-mouse IgG-peroxidase conjugate was purchased from
Southern Biotech (Birmingham, AL). All culture media components were from Invitrogen
(Carlsbad, CA).
BALB/c mice, 5 weeks of age, were purchased from The Jackson Laboratory (Bar Harbor,
ME). Mice were housed following the NIH guidelines and all procedures were approved by
the UNC Institutional Animal Care and Use Committee. BALB/c-derived colon carcinoma
CT26 cells were purchased from American Type Culture Collection (ATCC) (Manassas,
VA) and cultured in Dulbecco's Modified Eagle Medium with low (1 g/L) glucose
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.
Shown below is the nucleotide sequence of the CpG ODN, known as CpG 1826 in the
literature, and the structure of its DNP derivative. A control ODN used, designated as DNP-
ss, has the same nucleotide composition as the CpG 1826 but does not have any CpG motif:
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5′- TCCAGGACTTCTCTCAGGTT-3′. This sequence is commonly referred to as 1982 in
the literature.14 These ODN and their DNP derivatives were synthesized with a
phosphorothioate backbone by Dr. Rowshon Alam of the Nucleic Acid Core Facility of the
Program Project Grant in Pharmacodynamics of Genes and Oligonucleotides at the
University of North Carolina at Chapel Hill.
Vaccine Preparation and Active Immunization
Exact procedures in detail can be found elsewhere.1 To prepare the primary vaccine, 20 mg
of DNP-KLH was dissolved in 10 ml of endotoxin-free water to give a 2 mg/ml solution.
Prior to vaccination, an equal volume of CFA was added. The mixture was emulsified by
vortexing at maximum rpm for 15 minutes using a multi-tube vortexer (VWR, West Chester,
PA). Secondary vaccines were prepared similarly, but using IFA instead of CFA.
BALB/c mice were immunized intraperitoneally with 0.2 ml of freshly prepared primary
vaccine. A booster injection was given 2 weeks later using 0.2 ml of the secondary vaccine.
Anti-DNP antibody titer was monitored by enzyme-linked immunosorbent assay (ELISA) as
described below. In the first series of experiments, another booster injection was given 5
weeks after the first booster to maintain a high antibody titer.
Antibody Titer
In both series of experiments, 4 mice were selected at random for antibody titer bleeds and
were used throughout the entire duration of the experiment. Samples were collected before
immunization to establish background antibody levels and were then collected every 2
weeks. Blood samples, each 50 μl, were collected by tail clip into non-heparanzied
microcapillary tubes. Blood samples were allowed to clot at room temperature (RT) for up
to 1 hr and were then centrifuged at 12,000 × g for 5 min. Serum fractions were collected
and diluted 10-fold in PBS. Anti-DNP IgG titers were determined by ELISA as described
elsewhere.1 Briefly, 96-well plates were first coated with DNP-BSA solution/carbonate
buffer at pH 9.6 and incubated overnight at 4°C. Wells were washed in triplicate with PBS
containing 0.1% Tween 20 and then blocked with casein/PBS for 2 hr at RT. Wells were
then washed again in triplicate and incubated with 50 μl of serially diluted serum samples in
PBS and incubated for 2 hr at RT. After a triplicate wash, wells were incubated with of goat
anti-mouse IgG-peroxidase conjugate in PBS for 2 hr at RT. Wells were washed in triplicate
and incubated with 125 μl per well of a 1 mg/ml OPD solution for 20 min at RT. The
colorimetric reaction was terminated by the addition of a sulfuric acid solution. Absorbance
at 492 nm was measured on a Bio-Rad 3550 Microplate Reader. Best-fit sigmoidal curves
were obtained from plotting absorbances vs. log dilution factors using GraphPad Prism 4
(La Jolla, CA). Titer levels were obtained as EC50 values from the midpoint of each
sigmoidal curve.
Tumor Inoculation, Tumor Measurements and Dosing Schedule
Four to 5 weeks after primary vaccination, DNP-immunized mice were inoculated with 2.5
× 105 CT26 cells suspended in 0.1 ml HBSS into the right flank. Tumors were monitored
daily and measured every 2 or 3 days with an electronic digital caliper. Tumor volumes were
calculated based on the formula for an ellipsoid: length × width2 × π/6. Mice were
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euthanized when tumors exceeded 2.0 cm in any dimension. Treatments began 9 days after
inoculation when tumor sizes were between 75 to 150 mm3.
In the first series of experiments, 24 mice were divided evenly into 3 groups: DNP-ss via IV
(negative control), DNP-CpG via IV (positive control), and DNP-CpG via SC (test). Mice of
IV group were given a bolus dose that is equivalent to 100 μg of CpG ODN in 100 μl of
PBS via the tail vein. Mice of SC group were given the same dose into the left flank
(contralateral to the tumor). Three doses were given in 7-day intervals followed by 3
additional doses at 3-day intervals for a total of 6 doses.
In the second series of experiments, only SC route of administration was tested with 29 mice
in 3 groups: DNP-ss (negative control, n=9), free CpG (test, n=10), and DNP-CpG (test,
n=10). Five doses equivalent to 100 μg CpG ODN in 100 μl of PBS were administered
every 5 days. Tumor monitoring, measurements, and animal euthanasia were as described
above.
Statistical Analysis
Using Van der Waerden normal scores, a nonparametric pair-wise comparison test was
performed to determine if there were statistical differences in tumor volumes between each
group at each day. Statistical analyses were performed with the SAS statistical software by
Dominic T. Moore of the UNC Lineberger Comprehensive Cancer Center Biostatistics and
Data Management.
Results and Discussion
As shown in Fig. 1 and as found in an earlier study,1 IV administration of DNP-CpG 1826
conjugate exhibited anti-tumor activity in DNP-immunized mice. With the control DNP-
CpG 1982, which do not have any CpG motif but with the same nucleotide composition,
tumor growth proceeded. Most notable is that SC administration of DNP-CpG was not only
highly effective but also comparable to the IV route. When tumor burden was low, almost
complete tumor regression was observed with only a few doses. When tumor growth rate
noticeably increased, dosing frequency was increased to every 3 days and once again partial
tumor regression was achieved. Note that in this experiment, a third immunization was made
to keep anti-DNP titer high throughout the treatment schedule. The omission of additional
control groups of non-immunized and immunized mice treated with PBS were warranted
based on previous studies.1 Furthermore, the DNP hapten has been thoroughly studied and
exhibits no anti-cancer effects thereby deeming further DNP-related test groups to be
unnecessary.
The ability of SC administration to achieve such a remarkable anti-tumor effect is, to the
best of our knowledge, reported here for the first time in the literature and is attributed to
multiple reasons. Since tissue antibody levels are normally in equilibrium with intravascular
antibody levels at approximately half of the plasma concentration,11 it is reasonable to
believe that immune complexes can be readily formed at or near the injection site. The
increase in apparent MW from approximately 7 kDa of DNP-CpG to 160 kDa for a 2:1
ODN: anti-DNP IgG immune complex should amplify the depot effect usually associated
with an SC injection. This would allow for a prolonged and sustained release of immune-
complexed DNP-CpG over time to the circulation. Drainage from the injection site to lymph
nodes would occur via the lymphatic system. It is thus conceivable that DNP-CpG in
immune complexes can be presented in a more direct manner to dendritic cells and
macrophages in the lymph node, which would initiate the adaptive immune response leading
to anti-tumor activity. One could further postulate a possible involvement of Fc gamma
receptor on the target cell in the uptake of immune complexes.15,16
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In a second series of experiments, results of which are shown in Fig. 2, only SC route of
administration was employed and only one booster immunization was given. The failure of
the SC administration of DNP-ss to inhibit tumor development was as expected, as in the
case of IV administration of the same. This control group of mice was sacrificed earlier than
the treatment groups following the guideline of Institutional Animal Care and Use
Committee. In our protocol, the treatment group was allowed to develop tumors slightly
larger than control group. Tumors reached a maximum allowable size and quickly became
ulcerated. Since only one booster was given, anti-DNP titers were high at the start of dosing,
but started to fall between Dose 2 and 5.
Consistent with the SC data on Fig. 1, DNP-CpG 1826 was able to induce partial regression
as long as the anti-DNP titer was high. However, the treatment failed to inhibit tumor
growth as the titer decreased. When the titer dropped substantially on Day 20 and beyond,
the DNP-CpG treatments were not effective at all in suppressing tumor growth. At this
point, tumor growth rate was rapid and mirrored the growth rate with the free CpG treatment
group. Interestingly free CpG ODN also showed some anti-tumor effect upon SC injection.
Although these mice were also immunized with DNP, immune complexes are unable to
form because the ODN used was not derivatized with DNP. Free CpG ODN can also drain
to the lymph node, albeit more rapidly than immune complexes, following the steps
postulated earlier.
Although the DNP-CpG treatment group showed a slower tumor growth than the group
treated with free CpG, the profiles of tumor growth observed with DNP-CpG and free CpG
are remarkably similar to each other. This observation is attributed to the likelihood that
DNP-CpG exists largely as unbound just like free CpG because of low anti-DNP titer after
Day 10. Note that there is only 8% difference in MW between DNP-CpG and CpG, and thus
almost an identical rate of lymphatic transport is expected. Since this anti-tumor effect was
not seen with IV data1, further study is required.
Statistical analysis indicates that tumor volumes were not statistically different when
treatments began. Differences were deemed significant if p-values were less than 0.05.
DNP-CpG already showed statistical significance on Day 2 when compared to DNP-ss, but
no statistical difference was seen with free CpG until Day 7. Except for those days and at
Day 15, which was borderline significant, tumor volumes were statistically significant
between DNP-CpG and free CpG.
In summary, the importance of antibody titer is evident in the two series of experiments. An
inverse correlation was observed between antibody titer and tumor size. Partial tumor
regression and higher inhibition of tumor growth observed with DNP-CpG in DNP-
immunized mice reflect the enhanced anti-tumor effects of immune complexation over free
CpG treatments. An implication for future studies is the importance of maintaining a high
fraction of the ODN in the form of an immune complex.
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Comparison of tumor growth inhibition between SC and IV dosing of DNP-CpG in DNP-
immunized, CT26 tumor-bearing mice among: IV dosing of DNP-ss (negative control,
n=10), IV dosing of DNP-CpG (n=10), and SC injection of DNP-CpG (n=10). Tumor
volumes were plotted against time in days after administration of the first dose. Data are
expressed as means ± SD.
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Comparison of tumor growth inhibition between free CpG and DNP-CpG during SC dosing
in immunized mice. Tumor growth inhibition by subcutaneous administration of DNP-ss
(negative control, n=9), free CpG (n=10), and DNP-CpG (n=10) in DNP-immunized, CT26
tumor-bearing mice. Tumor volumes were plotted against time in days after administration
of the first dose. Data are expressed as means ± SD. Anti-DNP IgG titer measurements are
overlaid and expressed as means ± SD.
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